Incannex Healthcare Inc. (IXHL): Capital Expenditures
$10.0K
Year ended 2026-06-30
$8.0K
Trailing 12 months to 2026-09-30
-68.4%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $10.0K | +25.0% | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | $8.0K | -97.1% | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | $277.0K | -12.3% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $316.0K | n/a | 2024-09-30, From 2022-07-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $10.0K | +25.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.84B | +55.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
Compare IXHL, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗